MSPR/Ron [p Tyr1238, p Tyr1239, p Tyr1239] Antibody [Unconjugated]

HAF008). A specific band was detected for Phospho-MSP R/Ron (Y1238/Y1239) at approximately 170 kDa (as indicated). This experiment was conducted under reducing conditions and using Immunoblot Buffer Group 1." > HAF008). A specific band was detected for Phospho-MSP R/Ron (Y1238/Y1239) at approximately 170 kDa (as indicated). This experiment was conducted under reducing conditions and using Immunoblot Buffer Group 1." title="Western blot shows lysates of MDA-MB-453 human breast cancer cell line untreated (-) or treated (+) with 100 µM pervanadate (PV) for 10 minutes. The membranes were untreated or treated with calf intestinal phosphatase (CIP). PVDF membrane was probed with 1 µg/mL of Human Phospho-MSP R/Ron (Y1238/Y1239) Antigen Affinity-purified Polyclonal Antibody, followed by HRP-conjugated Anti-Rabbit IgG Secondary Antibody (Catalog # HAF008). A specific band was detected for Phospho-MSP R/Ron (Y1238/Y1239) at approximately 170 kDa (as indicated). This experiment was conducted under reducing conditions and using Immunoblot Buffer Group 1." />

Western blot shows lysates of MDA-MB-453 human breast cancer cell line untreated (-) or treated (+) with 100 µM pervanadate (PV) for 10 minutes. The membranes were untreated or treated with calf intestinal phosphatase (CIP). PVDF membrane was probed with 1 µg/mL of Human Phospho-MSP R/Ron (Y1238/Y1239) Antigen Affinity-purified Polyclonal Antibody, followed by HRP-conjugated Anti-Rabbit IgG Secondary Antibody (Catalog # <a class=

352-MS) for 10 minutes. MSP R/Ron (Y1238/Y1239) was immunoprecipiated with 1 ug Goat Anti-Human MSP R/Ron Antigen Affinity-purified Polyclonal Antibody(Catalog # AF691). The MSP R/Ron (Y1238/Y1239)-antibody complexes were absorbed using Protein G Sepharose. Immunoprecipitated MSP R/Ron (Y1238/Y1239) was detected by Western blot using 0.1 µg/mL of Rabbit Anti-Human Phospho-MSP R/Ron (Y1238/Y1239) Antigen Affinity-purified Polyclonal Antibody (Catalog # AF1947)." > 352-MS) for 10 minutes. MSP R/Ron (Y1238/Y1239) was immunoprecipiated with 1 ug Goat Anti-Human MSP R/Ron Antigen Affinity-purified Polyclonal Antibody(Catalog # AF691). The MSP R/Ron (Y1238/Y1239)-antibody complexes were absorbed using Protein G Sepharose. Immunoprecipitated MSP R/Ron (Y1238/Y1239) was detected by Western blot using 0.1 µg/mL of Rabbit Anti-Human Phospho-MSP R/Ron (Y1238/Y1239) Antigen Affinity-purified Polyclonal Antibody (Catalog # AF1947)." title="Human Phospho-MSP R/Ron (Y1238/Y1239) was immunoprecipitated from 1 mg of lysates of MDA-MB-453 human breast cancer cell line untreated (-) or treated (+) with 100 uM Pervanadate (PV) for 10 minutes or 100 ng/mL Recombinant Human MSP/MST1 Protein (Catalog # 352-MS) for 10 minutes. MSP R/Ron (Y1238/Y1239) was immunoprecipiated with 1 ug Goat Anti-Human MSP R/Ron Antigen Affinity-purified Polyclonal Antibody(Catalog # AF691). The MSP R/Ron (Y1238/Y1239)-antibody complexes were absorbed using Protein G Sepharose. Immunoprecipitated MSP R/Ron (Y1238/Y1239) was detected by Western blot using 0.1 µg/mL of Rabbit Anti-Human Phospho-MSP R/Ron (Y1238/Y1239) Antigen Affinity-purified Polyclonal Antibody (Catalog # AF1947)." />

Human Phospho-MSP R/Ron (Y1238/Y1239) was immunoprecipitated from 1 mg of lysates of MDA-MB-453 human breast cancer cell line untreated (-) or treated (+) with 100 uM Pervanadate (PV) for 10 minutes or 100 ng/mL Recombinant Human MSP/MST1 Protein (Catalog # <a class=

The expression and activity of Ron receptor isoforms in primary tumors and high-grade serous ovarian (HG-SOC) PDXsA. Upper panel displays western blot analysis of tumor lysates from patients assayed for phosphorylated (active) sfRon and Ron. Lower panel shows western blot analysis of total levels of Ron isoforms. The higher molecular weight sfRon bands (sfRon-HMW), which are putative, posttranslationally modified sfRon forms were also noted. The blots were stripped and re-probed for beta -actin. Lanes represent: healthy ovary (1, 2, 3); ovarian adenocarcinoma (4); carcinosarcoma (5); endometrioid adenocarcinoma (6) and HG-SOC (7). B. Upper panel displays western blot analysis of tumor lysates from HG-SOC PDXs assayed for phosphorylated Ron isoforms. Lower panel shows western blot analysis of total levels of Ron isoforms. The blots were stripped and re-probed for beta -actin or GAPDH. C. The expression of Ron isoforms was assessed by WES capillary electrophoresis-based protein assay in OVCAR3-sfRon cell line engineered to express sfRon vs. parental OVACR3 cells and compared with sfRon positive or negative HG-SOC PDXs. GAPDH was used as loading control. Image collected and cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/27551332), licensed under a CC-BY license. Not internally tested by R&D Systems.

The expression and activity of Ron receptor isoforms in primary tumors and high-grade serous ovarian (HG-SOC) PDXsA. Upper panel displays western blot analysis of tumor lysates from patients assayed for phosphorylated (active) sfRon and Ron. Lower panel shows western blot analysis of total levels of Ron isoforms. The higher molecular weight sfRon bands (sfRon-HMW), which are putative, posttranslationally modified sfRon forms were also noted. The blots were stripped and re-probed for beta -actin. Lanes represent: healthy ovary (1, 2, 3); ovarian adenocarcinoma (4); carcinosarcoma (5); endometrioid adenocarcinoma (6) and HG-SOC (7). B. Upper panel displays western blot analysis of tumor lysates from HG-SOC PDXs assayed for phosphorylated Ron isoforms. Lower panel shows western blot analysis of total levels of Ron isoforms. The blots were stripped and re-probed for beta -actin or GAPDH. C. The expression of Ron isoforms was assessed by WES capillary electrophoresis-based protein assay in OVCAR3-sfRon cell line engineered to express sfRon vs. parental OVACR3 cells and compared with sfRon positive or negative HG-SOC PDXs. GAPDH was used as loading control. Image collected and cropped by CiteAb from the following open publication (//pubmed.ncbi.nlm.nih.gov/27551332), licensed under a CC-BY license. Not internally tested by R&D Systems.

• Reactivity: Hu
• Applications: WB
• Clonality: Polyclonal
• Host: Rabbit
• Conjugate: Unconjugated
• Concentration: LYOPH

MSPR/Ron [p Tyr1238, p Tyr1239, p Tyr1239] Antibody [Unconjugated] Summary

• Immunogen: Phosphopeptide containing human MSP R/Ron Y1238/Y1239 sites
• Modification: p Tyr1239, p Tyr1238, p Tyr1239
• Specificity: The antibody detects endogenous human MSP R/Ron phosphorylated at Y1238/Y1239 using Western blots.
• Source: N/A
• Isotype: IgG
• Clonality: Polyclonal
• Host: Rabbit
• Gene: MST1R
• Purity Statement: Antigen and protein A Affinity-purified

Applications/Dilutions

• Dilutions:
  • Western Blot 1 ug/mL

Packaging, Storage & Formulations

• Storage: Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
  • 12 months from date of receipt, -20 to -70 °C as supplied.
  • 1 month, 2 to 8 °C under sterile conditions after reconstitution.
  • 6 months, -20 to -70 °C under sterile conditions after reconstitution.
• Buffer: Lyophilized from a 0.2 μm filtered solution in PBS with Trehalose. *Small pack size (SP) is supplied either lyophilized or as a 0.2 µm filtered solution in PBS.
• Preservative: No Preservative
• Concentration: LYOPH
• Reconstitution Instructions: Reconstitute at 0.2 mg/mL in sterile PBS.

Notes

This product is produced by and ships from R&D Systems, Inc., a Bio-Techne brand.

Alternate Names for MSPR/Ron [p Tyr1238, p Tyr1239, p Tyr1239] Antibody [Unconjugated]

• CD136 antigen
• CD136
• CDw136c-met-related tyrosine kinase
• EC 2.7.10
• EC 2.7.10.1
• macrophage stimulating 1 receptor (c-met-related tyrosine kinase)
• MSP R
• MSP receptor
• MSPR
• MST1R
• p185-Ron
• Protein-tyrosine kinase 8
• PTK8 protein tyrosine kinase 8
• PTK8
• Ron
• RONmacrophage-stimulating protein receptor
• soluble RON variant 1
• soluble RON variant 2
• soluble RON variant 3
• soluble RON variant 4

Background

Macrophage stimulating protein receptor (MSP R), also known as Ron, is one of a small family of receptor tyrosine kinases (RTKs) that also includes human Met and chicken Sea. Each family member is synthesized as a single-chain precursor that is cleaved into a mature disulfide-linked heterodimer composed of an extracellular alpha  chain and a membrane-spanning beta  chain with intrinsic tyrosine kinase activity. MSP R/Ron is overexpressed in a number of primary breast carcinomas and non-small cell lung carcinomas, suggesting a role for this RTK in mammary and lung tumor progression. Phosphorylation of MSP R/Ron at Y1238/Y1239 in the activation loop of the kinase domain is responsible for kinase activity.

Limitations

This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.

Publications for MSPR/Ron Antibody (AF1947)(14)

Publications using AF1947

• Wang, KJ;Ye, SZ;Jia, XL;Wang, KY;Meng, XY;Fei, X;Ye, SJ;Ma, Q; RON receptor tyrosine kinase as a critical determinant in promoting tumorigenic behaviors of bladder cancer cells through regulating MMP12 and HIF-2? pathways Cell death & disease 2024-11-19 [PMID: 39557851] (Western Blot, Human)
• Hayashi, SY;Craddock, BP;Miller, WT; Effects of heterologous kinase domains on growth factor receptor specificity Cellular signalling 2024-07-22 [PMID: 39048037] (Western Blot, Human)
• Lindsay M. Gurska, Rachel Okabe, Alexandra Schurer, Meng Maxine Tong, Mark Soto, Daniel Choi et al. Crizotinib Has Preclinical Efficacy in Philadelphia-Negative Myeloproliferative Neoplasms Clinical Cancer Research 2023-03-01 [PMID: 36537918]
• DM Beauvais, SE Nelson, KM Adams, NA Stueven, O Jung, AC Rapraeger Plasma membrane proteoglycans syndecan-2 and syndecan-4 engage with EGFR and RON kinase to sustain carcinoma cell cycle progression The Journal of Biological Chemistry, 2022-05-13;0(0):102029. 2022-05-13 [PMID: 35569509] (Immunoprecipitation, Human)
• Carolina Franco Nitta, Ellen W Green, Elton D Jhamba, Justine M Keth, Iraís Ortiz-Caraveo, Rachel M Grattan et al. EGFR transactivates RON to drive oncogenic crosstalk eLife 2021-11-25 [PMID: 34821550]
• Q Yu, J Wang, T Li, X Guo, S Ding, X Che, L Zhu, Y Peng, X Xu, G Zou, X Zhang Recepteur d&#039;origine nantais contributes to the development of endometriosis via promoting epithelial-mesenchymal transition of a endometrial epithelial cells Journal of Cellular and Molecular Medicine, 2021-01-06;0(0):. 2021-01-06 [PMID: 33410267] (Western Blot, Human)
• D Dustin, G Gu, AR Beyer, SK Herzog, DG Edwards, H Lin, TL Gonzalez, SL Grimm, C Coarfa, DW Chan, BJ Kim, JP De La O, MJ Ellis, D Liu, S Li, AL Welm, SAW Fuqua RON signalling promotes therapeutic resistance in ESR1 mutant breast cancer British Journal of Cancer, 2020-12-01;0(0):. 2020-12-01 [PMID: 33257837] (Western Blot, Human)
• P Berning, C Hennemann, C Tulotta, C Schaefer, B Lechtape, M Hotfilder, Y El Gourari, H Jürgens, E Snaar-Jaga, G Hempel, U Dirksen, J Potratz The Receptor Tyrosine Kinase RON and Its Isoforms as Therapeutic Targets in Ewing Sarcoma Cancers (Basel), 2020-04-07;12(4):. 4/7/2020 [PMID: 32272784]
• M Balmaña, F Diniz, T Feijão, CC Barrias, S Mereiter, CA Reis Analysis of the Effect of Increased &amp;alpha2,3-Sialylation on RTK Activation in MKN45 Gastric Cancer Spheroids Treated with Crizotinib Int J Mol Sci, 2020-01-22;21(3):. 2020-01-22 [PMID: 31979110] (ICC, Human)
• R Graves-Dea, G Bogatcheva, S Rehman, Y Lu, JN Higginboth, B Singh Broad-spectrum receptor tyrosine kinase inhibitors overcome de novo and acquired modes of resistance to EGFR-targeted therapies in colorectal cancer Oncotarget, 2019-02-12;10(13):1320-1333. 2019-02-12 [PMID: 30863492] (Western Blot, Human)
• Sasha J. Ruiz-Torres, Nancy M. Benight, Rebekah A. Karns, Elyse E. Lower, Jun-Lin Guan, Susan E. Waltz HGFL-mediated RON signaling supports breast cancer stem cell phenotypes via activation of non-canonical beta -catenin signaling Oncotarget 2017-08-29 [PMID: 28938607]
• Jeffery Chakedis, Randall French, Michele Babicky, Dawn Jaquish, Evangeline Mose, Peter Cheng et al. Characterization of RON protein isoforms in pancreatic cancer: implications for biology and therapeutics Oncotarget 2016-07-19 [PMID: 27323855]
• Ota M, Horiguchi M, Fang V, Shibahara K, Kadota K, Loomis C, Cammer M, Rifkin D Genetic suppression of inflammation blocks the tumor-promoting effects of TGF-beta in gastric tissue. Cancer Res, 2014-03-03;74(9):2642-51. 2014-03-03 [PMID: 24590056] (IHC, Mouse)
• Thobe MN, Gurusamy D, Pathrose P, Waltz SE The Ron receptor tyrosine kinase positively regulates angiogenic chemokine production in prostate cancer cells. Oncogene, 2009-10-19;29(2):214-26. 2009-10-19 [PMID: 19838218] (Western Blot, Human)

Bioinformatics

• Gene Symbol: MST1R